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included external structures (cornea) in addition to uvea. 
Seven domains and 15 items were identified: best-corrected 
visual acuity, inflammation of the anterior chamber (ante-
rior chamber cells, hypopyon, the presence of fibrin, active 
posterior keratic precipitates and iris nodules), intraocu-
lar pressure, inflammation of the vitreous cavity (vitreous 
haze, snowballs and snowbanks), central macular edema, 
inflammation of the posterior pole (the presence and num-
ber of choroidal/retinal lesions, vascular inflammation and 
papillitis), and global assessment from both (patient and 
physician). From all the variables studied in the multivari-
ate model, anterior chamber cell grade, vitreous haze, cen-
tral macular edema, inflammatory vessel sheathing, papil-
litis, choroidal/retinal lesions and patient evaluation were 
Abstract To develop a disease activity index for patients 
with uveitis (UVEDAI) encompassing the relevant domains 
of disease activity considered important among experts in 
this field. The steps for designing UVEDAI were: (a) Defin-
ing the construct and establishing the domains through 
a formal judgment of experts, (b) A two-round Delphi 
study with a panel of 15 experts to determine the relevant 
items, (c) Selection of items: A logistic regression model 
was developed that set ocular inflammatory activity as the 
dependent variable. The construct “uveitis inflammatory 
activity” was defined as any intraocular inflammation that 
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included in UVEDAI. UVEDAI is an index designed to 
assess the global ocular inflammatory activity in patients 
with uveitis. It might prove worthwhile to motorize the 
activity of this extraarticular manifestation of some rheu-
matic diseases.
Keywords Uveitis · Activity index · Ocular inflammation · 
Outcome measures
Introduction
Uveitis is defined as inflammation of the uvea, the vascular 
middle layer of the eye. The term refers to a great num-
ber of diseases characterized by intraocular inflammation 
involving the uvea and other ocular structures (retina, vit-
reous cavity and retinal vessels) [1]. It may be character-
ized as having a poor visual prognosis and remains one of 
the leading blinding disorders [2, 3]. Uveitis is an extraar-
ticular manifestation frequently found in many rheumatic 
diseases (spondyloarthropathy, Behçet, sarcoidosis, lupus, 
vasculitis, etc.) and may cause significant morbidity. In 
some patients, such as those with Behçet disease or spon-
dyloarthritis, uveitis is often the origin of the main symp-
toms of the disease. Consequently, the implementation of 
interdisciplinary units—ophthalmology and rheumatol-
ogy—assumes considerable relevance in the assessment 
and management of these patients.
The Standardization of Uveitis Nomenclature Work-
ing Group [4, 5] (SUN) developed criteria based on the 
primary anatomic location of inflammation within the eye 
(International Uveitis Study Group [6]), as well as criteria 
for onset, duration, course and disease activity. The SUN 
criteria for the classification of uveitis have become the 
standard when publishing uveitis data, ensuring greater 
analytical rigor when comparing studies. However, such 
criteria only take into account inflammation in the anterior 
chamber and vitreous haze when defining uveitis activity.
Standardized and validated outcome measures of disease 
activity are lacking in uveitis management, which makes 
it difficult to compare efficacy and response to treatment 
[7–9]. In addition, the activity of uveitis is not recorded 
by the usual articular indexes that are used by rheumatolo-
gists to monitoring disease activity and function such as 
BASDAI, BASFI or ASDAS. In this line, Denniston et al. 
[9] carried out a systematic review of clinical trial or treat-
ments for uveitis, highlighting the heterogeneity of primary 
outcomes and arguing that the complex issue of selecting 
outcome measures for clinical trials of efficacy related to 
uveitis needs to be addressed.
As in rheumatology, the validation of outcome measures 
and the development of a disease activity index [10–12] 
can be a major advance in clinical trials as well as in evalu-
ation of treatment response of patients with uveitis in daily 
clinical practice.
The objectives of the current study were to develop a 
disease activity index for patients with uveitis (UVEDAI) 
that would include relevant domains of disease activity 
considered important among experts in uveitis.
Methods
Development of UVEDAI
The index has been developed according to the criteria 
described in the Outcome Measures in Rheumatology Clin-
ical Trials (OMERACT) [13].
A formal interdisciplinary working group for uveitis, 
consisting of eight ophthalmologists and seven rheuma-
tologists, was formed. The participants had relevant expe-
rience in the management of all types of uveitis and work 
in interdisciplinary uveitis units at hospitals in the Span-
ish national health system. Chronological steps to design 
UVEDAI:
1. Definition of the construct and establishment of 
domains: The consensus technique used was the formal 
judgment of experts, which represents the informed 
opinion of people with experience in the subject, who 
are recognized by others as skilled in the topic, and 
who can provide information, evidence, judgments and 
assessments [14]. A consensus meeting took place in 
October 2011 in Madrid, coordinated by a methodolo-
gist with training and experienced in this technique, 
and all the members participated. First, one or two indi-
ces of activity, based on the anatomic location, were 
discussed, which the expert panel decided by consen-
sus to build into a global index. Second, the construct 
“uveitis inflammatory activity” was defined as any 
intraocular inflammation including external structures 
(cornea) in addition to uvea, and the domains and items 
were established. Seven domains were identified: best-
corrected visual acuity (BCVA), inflammation of the 
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anterior chamber, intraocular pressure, inflammation 
of the vitreous cavity, central macular edema (ME), 
inflammation of the posterior pole and global assess-
ment.
2. Determination of items: The panel selected 15 relevant 
items that would thereafter be tested to derive the new 
disease activity index. A two-round Delphi consensus 
technique was used by the panel to achieve consensus. 
Agreement on the utility of each item to assess “uvei-
tis inflammatory activity” was evaluated using a Likert 
scale (1 [strongly disagree] to 5 [strongly agree]). The 
degree of agreement (DA) among the working group 
for each item was high (DA > 85%). In the first round, 
12 items reached DA > 85% and the three remaining 
reached DA > 85% after the second round, and thus 
were included in UVEDAI.
 As result, seven domains and 15 items were identified: 
best-corrected visual acuity, inflammation of the ante-
rior chamber (anterior chamber (AC) cells, hypopyon, 
the presence of fibrin, active posterior keratic precipi-
tates and iris nodules: five items), intraocular pressure, 
inflammation of the vitreous cavity (vitreous haze, 
snowballs and snowbanks: three items), central macu-
lar edema, inflammation of the posterior pole (the pres-
ence and number of choroidal/retinal lesions, vascular 
inflammation and papillitis: three items) and global 
assessment from both the patient and physician (two 
items).
3. Selection of items: A logistic regression model was 
constructed, the ordinal dependent variable of which 
was ocular inflammatory activity (with three catego-
ries: mild, moderate and severe) and as variables pre-
dictive, the items mentioned above. After building the 
first model, the variables were eliminated in inverse 
order of their significance level to obtain the minimal 
model explaining the maximum variability. The capa-
bility of the final model to discriminate patients with 
uveitis according to the level of inflammatory activity 
was then determined.
Items and operational definitions
Inflammatory activity of uveitis was considered the pri-
mary endpoint. This variable was defined as any intraocu-
lar inflammation, and it was categorized as mild, moderate 
and severe at the discretion of the ophthalmologist follow-
ing patient assessment. The manner in which each hospital 
carried out the evaluations was homogenized, and the CIR-
RUS spectral domain (Carl Zeiss) was the optical coher-
ence tomography (SD-OCT) equipment used in all centers.
Clinical evaluations included visual acuity (best-cor-
rected Snellen visual acuity) and ophthalmic examination. 
A slit-lamp examination was used to evaluate the anterior 
segments. AC cells were graded according to the classifi-
cation established by the SUN [4]. Intraocular pressure 
[15] was determined by using a contact tonometer (Gold-
mann). Indirect ophthalmoscopy was also performed in 
all patients to evaluate the vitreous and posterior segments 
[16]. The Nussenblatt scale [17] was adapted for any vit-
reous haze that had been graded as mild or severe (1–2+ 
or 3–4+, respectively). SD-OCT was used in all patients to 
determine the presence of macular edema [18], which was 
defined as a central retinal thickness greater than 315 μm. 
The 1-mm central retinal thickness was evaluated using the 
macular cube strategy.
An overall assessment of the disease by both patient and 
researcher was made using a visual analog scale (VAS) of 
0–10 cm, 0 being the lowest (best) possible disease activity 
and 10 the highest (worst). VAS assessments of patient and 
physician were performed with the following questions; 
VAS patient: “at the present time, how would you rate your 
eyesight using both eyes (with glasses or contact lenses, if 
you wear them): excellent, good, fair, poor, or very poor, 
or are you completely blind”. VAS physician: “taking into 
account eye inflammation and macular edema, indicate 
your assessment of disease activity experienced by this 
patient”.
Selection and recruitment of patients
Patients diagnosed with uveitis at nine multidisciplinary 
uveitis units in hospitals from Spanish National Health Sys-
tem were invited to participate in the study. The recruitment 
period was from March 2013 to July 2014. Consecutive 
patients were eligible for inclusion during the recruitment 
period, with one out of two patients who met the selection 
criteria being enrolled until the sample size was reached. 
Inclusion criteria consisted of the following: signed informed 
consent by the patient or his/her legal representative, aged 
five years or older, patients diagnosed with active anterior, 
intermediate, posterior uveitis or panuveitis in at least one 
eye, and with active uveitis in at least one eye at the time 
of the selection visit. We excluded patients in complete uvei-
tis remission, those who had been diagnosed with surgical 
or traumatic endophthalmitis, and any patients then partici-
pating in a clinical trial or research project related to this or 
other health problems. For those patients with bilateral uvei-
tis, we took into account the fact that treatment decisions 
would always be based on the most inflamed eye. This study 
was performed following the principles outlined in the Hel-
sinki Declaration, and the study protocol was approved by 
the ethics committee at all participating hospitals.
The sample size was calculated based on at least 10 events 
per variable, as suggested in the current literature [19–21]. 
The presence of moderate or severe uveitis was regarded as 
an event. When the expected prevalence of such an event 
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reached 60%, we determined that 200 patients would be suf-
ficient for designing a model that would include up to 12 
variables (200 patients × 60% = 120 expected events, which 
corresponds to 120/10 possible variables).
Statistical analysis
The categorical variables were described using frequencies 
and percentages. These were compared among activity lev-
els using Chi-squared tests, and Fisher’s exact tests other-
wise. The variables that followed a normal distribution were 
described using the mean and standard deviation (SD), and 
the differences between groups of activity were assessed 
using ANOVA tests. Non-normally distributed variables 
were described with the median and interquartile interval 
(IQR), and differences between groups were assessed with 
the Kruskal–Wallis nonparametric test. In all the analyses, a 
p value <0.05 was considered statistically significant.
Given the ordinal nature of the outcome variable (uveitis: 
mild, moderate and severe), we adjusted the model using 
ordinal logistic regression. We followed the stepwise meth-
odology, including the potentially explanatory variables in 
the model, by statistical significance order. The selection of 
independent variables in the multivariate models was based 
on clinical judgments and those with a p value <0.20 in the 
bivariate analysis. After building the first model, we tested 
the deletion of each variable in inverse significance order 
to obtain the minimum model that would explain the maxi-
mum variability. The inclusion or exclusion of each varia-
ble was determined using a likelihood ratio test (LRT) with 
a 90% confidence level. The assumption of proportional 
odds across responses underlying the ordered logistic mod-
els was also verified using the approximate LRT with the 
same confidence level. Confidence intervals for the odds 
ratio were calculated at a 95% confidence level.
Regression coefficients in logarithmic format for the 
multivariate model were used to calculate the score used to 
define the ocular activity level of a given patient:
We used the resulting score to calculate a patient’s prob-
ability of being classified with mild, moderate or severe 
uveitis based on the following cumulative probabilities:
UVEDAI =
v∑
i=1
βi · xi
v = Number of variables included
βi = Logarithmic regression coefficient for variable i
xi = Variable i
From which we calculated probabilities for the three 
categories:
The patient was then classified in that category with the 
higher probability (see example in Supplementary Material).
The modeling accuracy was assessed using the area 
under the curve (AUC) [22–24]. To overcome any limita-
tions in the use of AUC for binary outcomes, and basing 
our calculations on proportional odds, we formulated two 
AUC measures of uveitis: one for discriminating mild ver-
sus moderate and severe activity levels and another for mild 
and moderate versus severe activity. In order to provide a 
measurement of the uncertainty of the model’s accuracy, 
we calculated the 95% percentile confidence intervals for 
the estimation of both AUCs by performing a nonparamet-
ric bootstrap estimation with 1000 replications. Using sam-
pling replacement, the bootstrap obtained 1000 replicates 
of the original dataset and coefficients of the final model. 
The corresponding AUCs were then estimated over each of 
these replicates. The 95% percentile confidence intervals 
for each AUC were represented by percentiles 2.5 and 97.5 
of the 1000 bootstrap point estimates’ distribution.
Additionally, the internal validity of the results was 
assessed by comparing the estimation of the AUC with an 
empirical distribution of the outcome in order to determine 
the probability of obtaining a better model accuracy by 
chance. For that purpose, we calculated 1000 replicates of 
the original outcome variable containing the exact number 
of cases of mild (n = 77), moderate (n = 93) and severe 
(n = 25) uveitis, but randomly distributed. The discrimina-
tion of mild versus moderate + severe diagnosis and the 
discrimination of mild + moderate versus severe diagno-
sis were assessed for each of the 1000 random replicates 
by calculating the AUC. The probability of obtaining by 
chance an AUC better than the original was calculated, 
dividing by 1000 the total number of cases in which the 
random AUC was better than the original AUC.
Results
Our initial sample contained 203 patients. After exclud-
ing missing values (n = 8), a total of 195 patients were 
Pr(uveitis = Mild) = Pr(uveitis < Moderate)
Pr(uveitis = Moderate) = Pr(uveitis < Severe)
− Pr(uveitis < Moderate)
Pr(uveitis = Severe) = 1− Pr(uveitis < Severe)
Pr(uveitis < moderate) =
[
1/
(
1 + e
(score−constant mild to moderate)
)]
= 1/
(
1 + e
(score−1.01)
)
Pr(uveitis < severe) =
[
1/
(
1 + e
(score−constant moderate to severe)
)]
= 1/
(
1 + e
(score−4.91)
)
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included in the study. Demographic characteristics and 
bivariate analysis are summarized in Table 1. The mean 
age was 45.8±16.1 years; 54% (n = 106) were female. 
Forty-eight percent (n = 93) presented moderate activ-
ity, 39% (n = 77) mild activity, and 13% (n = 25) severe 
activity.
Table 1  Description of demographic characteristics and bivariate analysis
a SD standard deviation, b VAS visual analog scale, c IQR interquartile interval
Variables Activity levels
All (N = 195) Mild (N = 77) Moderate (N = 93) Severe (N = 25) p
Sex, female, n (%) 106 (54) 42 (55) 52 (56) 12 (48) 0.770
Age, mean (SDa) 45.8 (16.1) 46.5 (15.7) 45.3 (17.1) 45.4 (13.8) 0.890
Patient VASb median (IQRc) 5.0 (2.0–7.0) 3.0 (2.0–6.0) 5.0 (2.0–7.0) 7.0 (6.0–8.0) <0.001
Physician VASb median (IQRc) 4.0 (2.0–6.0) 2.0 (2.0–3.0) 5.0 (3.0–6.0) 7.0 (6.0–8.0) <0.001
Eye, right n (%) 106 (54) 40 (52) 54 (58) 12 (48) 0.570
Anatomic location n (%)
 Anterior 100 (51.28) 56 (72.73) 37 (39.78) 7 (28) <0.001
 Intermediate 30 (15.38) 7 (9.09) 23 (24.73) 0 (0)
 Posterior 29 (14.87) 3 (3.9) 17 (18.28) 9 (36)
 Panuveitis 36 (18.46) 11 (14.29) 16 (17.2) 9 (36)
Visual acuity median (IQRc) 0.8 (0.4–1.2) 1.0 (0.5–1.2) 0.6 (0.3–1.0) 0.4 (0.2–0.8) <0.001
Anterior chamber cell grade n (%) <0.001
 0 49 (25) 9 (12) 32 (34) 8 (32)
 1+ 59 (30) 36 (47) 18 (19) 5 (20)
 2+ 48 (25) 26 (34) 21 (23) 1 (4)
 3+ 32 (16) 6 (8) 20 (22) 6 (24)
 4+ 7 (4) 0 (0) 2 (2) 5 (20)
Hypopyon median (IQRc) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.620
Fibrin in the anterior chamber n (%) 18 (9) 4 (5) 10 (11) 4 (16) 0.197
Keratic precipitates n (%) 104 (53) 42 (55) 48 (52) 14 (56) 0.890
Iris nodules n (%) 6 (3) 4 (5) 2 (2) 0 (0) 0.500
Intraocular pressure n (%) 0.013
 ≤21 mmHg 178 (91) 73 (95) 86 (92) 19 (76)
 >21 mmHg 17 (9) 4 (5) 7 (8) 6 (24)
Vitreous haze n (%) <0.001
 Null 117 (60) 59 (77) 49 (53) 9 (36)
 Mild (1–2+) 49 (25) 15 (19) 27 (29) 7 (28)
 Severe (3–4+) 26 (13) 3 (4) 16 (17) 7 (28)
Presence of snowballs n (%) 23 (12) 6 (8) 15 (16) 2 (8) 0.220
Snowbanks: number of clock hours, median (IQRc) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.640
Macular edema n (%) <0.001
 ≤315 μm 155 (79) 72 (94) 63 (68) 20 (80)
 >315 μm 40 (21) 5 (6) 30 (32) 5 (20)
Choroidal or retinal lesions: maximal size  
(disk diameter) median (IQRc)
0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–0.3) 0.198
Number of choroidal or retinal lesions n (%) 0.009
 0 166 (85) 72 (94) 77 (83) 17 (68)
 1–5 16 (8) 4 (5) 9 (10) 3 (12)
 ≥6 12 (6) 1 (1) 7 (8) 4 (16)
Exudative retinal detachment n (%) 4 (2) 0 (0) 4 (4) 0 (0) 0.185
Inflammatory vessel sheathing n (%) 38 (19) 7 (9.1) 19 (20.4) 12 (48) <0.001
Papillitis n (%) 18 (9) 2 (2.6) 10 (10.8) 6 (24) 0.004
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in Fig. 1. We plotted all of the possible values for the total 
score along the X-axis and the probability associated with 
each score along the Y-axis. The three curves represent 
the fluctuation in probability and the cross-point between 
curves that allowed for the determination of a score thresh-
old from which a uveitis status could be assigned (see Sup-
plementary Material for an example of calculations). The 
range of possible values for the scores was approximately 
−1 × 41 to 12 × 580. As can be observed in the graph, 
patients with a total score below 1 × 05 will be classified 
in the category of mild uveitis; those with a total score 
between 1·06 and 4·86 will be classified as having moder-
ate uveitis; and those with a total score greater or equal to 
4 × 87 will be classified as having severe uveitis.
Therefore, clinicians using this tool will only need 
to substitute the values for AC cell grade, vitreous haze, 
The results of the regression model summarized in 
Table 2 revealed that the uveitis activity levels were more 
severe in patients with high degrees of anterior chamber 
cell grade, high degrees of vitreous haze, central macular 
edema over 315μm, who presented inflammatory vessel 
sheathing, papillitis, an elevated number of choroidal/reti-
nal lesions and higher patient evaluation.
Table 2  Multivariate model of uveitis activity level in the study pop-
ulation
a LOG (OR) logistic regression (odds ratio)
Variables ORadjusted (95% CI) LOG (OR
a)
Anterior chamber cell grade (ref. 0)
 1+ 0.24 (0.10–0.60) −1.41
 2+ 0.49 (0.19–1.27) −0.72
 3+ 2.97 (1.04–8.49) 1.09
 4+ 27.85 (3.42–226.75) 3.33
Vitreous haze (ref. Null)
 Mild (1–2+) 1.46 (0.65–3.27) 0.38
 Severe (3–4+) 3.95 (1.40–11.16) 1.37
Macular edema, μm  
(ref. ≤315 μm)
3.58 (1.56–8.21) 1.28
Inflammatory vessel sheathing 
(ref. No)
4.43 (1.71–11.53) 1.49
Patient evaluation 1.23 (1.09–1.39) 0.21
Papillitis (ref. No) 4.05 (1.18–13.92) 1.40
Number of choroidal or retinal lesions (ref. 0)
 1–5 2.00 (0.63–6.35) 0.69
 ≥6 4.99 (1.08–23.01) 1.61
Constant
 Mild to moderate 1.01
 Moderate to severe 4.91
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Fig. 1  Probability of being classified with mild, moderate or severe 
uveitis according to the total score obtained
UVEDAI =



0.00 if ACC = 0
−1.41 if ACC = 1
−0.72 if ACC = 2
1.09 if ACC = 3
3.33 if ACC = 4



+



0.00 if VH = null
0.38 if VH = mild
1.37 if VH = severe



+
�
0.00 ifME ≤ 315
1.28 ifME > 315
�
+
�
0.00 if VS = no
1.49 if VS = yes
�
+ 0.21xPE+
�
0.00 if papilitis = no
1.40 if papilitis = yes
�
+



0.00 if no. RL = 0
0.69 if no. RL = 1 to 5
1.61 if no. RL ≥ 6



ACC: anterior chamber cell grade; VH: vitreous haze; VS: 
inflammatory vessel sheathing; PE: patient evaluation; RE: 
choroidal/retinal lesions.
The distribution of the probabilities of being classified 
in each of the 3 uveitis categories—based on the score 
obtained and the cut points for each category—is shown 
macular edema, inflammatory vessel sheathing, patient 
evaluation, papillitis and the number of choroidal/retinal 
lesions in the formula given, and with the score obtained, 
to classify a patient’s uveitis disease activity level accord-
ing to the established cut points: ≤1 × 05: mild; 1 × 06 to 
≤4 × 86: moderate; ≥4 × 87: severe.
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The discriminatory capacity of the resulting multivari-
ate model was 87% (95% CI 82–92%) for differentiating 
patients with mild uveitis from those with moderate or 
severe uveitis and 90% (95% CI 84–95%) for differentiat-
ing patients with mild or moderate uveitis from those with 
severe uveitis (Fig. 2). Additionally the results from the 
analysis for the internal validation revealed that for none of 
the 1000 replicates of the random distribution of the out-
come the resulting AUC was better than the original, mean-
ing the probability of obtaining by chance an AUC better 
than the obtained with the original model is <0.001.
Discussion
In our knowledge, this is the first study in which it is devel-
oped an activity index (UVEDAI) that attempts to classify 
patients with uveitis according to the degree of their ocular 
inflammatory activity. The results reported herein could be 
of interest to ophthalmologists, rheumatologists and other 
medical specialties that keep abreast of clinical investiga-
tion into systemic diseases with ocular involvement. Of 
all the variables investigated, anterior chamber cell grade, 
vitreous haze, central macular edema, inflammatory ves-
sel sheathing, papillitis, choroidal/retinal lesions and 
patient evaluation were the most important to determining 
the activity of uveitis. Our score showed an 87% capacity 
to differentiate patients with mild uveitis from those with 
moderate or severe uveitis and an 88% capacity for differ-
entiating patients with mild or moderate uveitis from those 
with severe uveitis.
Uveitis occurs in many patients who have a systemic 
rheumatic disease. In those with an established diagnosis 
of autoimmune disease, ocular inflammation can mark the 
severity of the systemic condition. We believe that assess-
ment of ocular activity as an index can be useful in the 
global management of patients with systemic inflamma-
tory diseases, especially in the assessment of treatment 
response.
The evaluation of cells in the anterior chamber is the 
accepted standard procedure for assessing inflamma-
tory activity in the anterior segment [4, 25]. It is worth 
remarking the protective effect of categories 1 (ORadjusted 
0.24; 95% CI 0.10–0.60) and 2 (ORadjusted 0.49; 95% CI 
0.19–1.27) of this variable in the multivariate model. The 
explanation of this effect is that 91.84% of the patients with 
grade 0 have intermediate uveitis, posterior or panuveitis 
not anterior uveitis. In these patients, the overall value of 
the UVEDAI is not affected because it is corrected from 
the coefficients of other variables that are involved, such 
as macular edema, vasculitis or others. Vitreous haze is 
the most widely accepted measure of inflammation in the 
vitreous cavity. This variable has often been used as a pri-
mary outcome in many randomized clinical trials [26–29]. 
Other significant factor on said score was macular edema, 
the most common cause of irreversible visual impairment 
in patients with uveitis but a treatable entity [30–33]. We 
believe that its clinical relevance, its relationship with 
chronic inflammatory activity and the ease of its imple-
mentation in an objective and reproducible way with SD-
OCT confirm the importance of its inclusion in UVEDAI. 
In the posterior pole, the presence of inflammatory vessel 
sheathing, choroidal/retinal lesions and papillitis has been 
established and characterized clinical variables indicating 
inflammatory activity and their presence is often a warn-
ing sign. Although in our study the number of patients with 
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these inflammatory events was reduced, they were nonethe-
less significant. According to this finding, and in line with 
the new clinical trials, which has incorporated the above-
mentioned parameters for the routine evaluation of clinical 
activity in uveitis [29], we regard these variables as truly 
significant in the composite index that has been devel-
oped. Another item bearing an important association is the 
patient evaluation.
On the other hand, variables, such as visual acuity, 
intraocular pressure, hypopyon, which are clinically rel-
evant in the routine assessment of patient with uveitis, have 
not proven to be statistically significant in our study. In the 
same way, however, they are clinical signs that must be 
routinely assessed in the evaluation of any eye with uveitis.
The inclusion of the SD-OCT in the assessment of mac-
ular edema derives from its wide availability in ophthal-
mologist outpatient clinics, its noninvasive approach, and 
the fact that it is considered the gold standard in diagnosing 
and monitoring of ME [31, 34].
The main strength of the developed UVEDAI is its 
usefulness as a standardized tool that relies on variables 
extracted from examinations established in routine clini-
cal practice, without complex equipment-based diagno-
ses. We believe that this composite index, which assesses 
global ocular inflammatory activity and classification, will 
not only allow clinicians to compare the uveitis activity, 
regardless of cause, but will also serve as a useful tool for 
future studies and trials when sensitivity to change will be 
analyzed. Just as in other disease activity score [11], UVE-
DAI assigns different weightings to each variable based on 
any of the ocular anatomic regions. Since these are often 
affected simultaneously, the result is a score that indicates 
global ocular inflammatory activity, which can accurately 
be classified as mild, moderate or severe.
One limitation is the use of the ophthalmologist’s clini-
cal judgment as the gold standard for classifying inflamma-
tory uveitis activity in mild, moderate and severe cases of 
the disease. Our decision was based on the fact that no gold 
standard set of criteria for ocular inflammatory activity with 
which to compare our index currently exists in the scientific 
literature. In fact, there are some articles in the literature 
that define the outcome as an “improvement” in activity 
according to clinical criteria [35–37]. Furthermore, clini-
cal judgment of the physician was also used in the devel-
opment, of other composite indices as popular as disease 
activity score (DAS) for rheumatoid arthritis [11]. Another 
limitation concerning the development phase of the index 
is the presence of a possible circularity between the pre-
dictor variables and the main variable. We will determine 
whether this potential circularity affects UVEDAI during 
an already programed validation phase in which patients 
will be independently evaluated and in a masked form by 
two ophthalmologists.
Another limitation that had to be overcome involved 
measuring the model’s discrimination capacity to verify 
the accuracy of ordinal logistic regression models against 
existing methods. It must be borne in mind, however, that 
ordinal logistic regression works under the assumption of 
proportional odds across responses; that is, each explana-
tory variable has the same effect at each cumulative split 
of the ordinal dependent variable (effect of mild vs. mod-
erate + severe ≈ effect of mild + moderate vs. severe). 
Keeping this in mind, and taking into account that our data 
did satisfy the proportional odds assumption, the use of 
two AUCs to measure the capacity to differentiate between 
patients with mild from those with moderate or severe uvei-
tis, as well as between patients with mild or moderate from 
those with severe uveitis, gives a good approximation of 
the total model accuracy.
In conclusion, the UVEDAI is the first ocular easy-to-use 
composite score based on variables commonly used in clini-
cal practice for uveitis assessment that assesses and classifies 
global ocular inflammatory activity with high discriminatory 
power. We believe that it could be a useful tool not only in 
daily clinical practice, but also for comparing results in clini-
cal and therapeutic studies. Further studies are required to 
validate this index and analyze its metric capacity.
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